PMID- 22892058
OWN - NLM
STAT- MEDLINE
DCOM- 20130405
LR  - 20221207
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Print)
IS  - 0022-3956 (Linking)
VI  - 46
IP  - 11
DP  - 2012 Nov
TI  - HPA-axis function, symptoms, and medication exposure in youths at clinical high 
      risk for psychosis.
PG  - 1389-93
LID - S0022-3956(12)00227-0 [pii]
LID - 10.1016/j.jpsychires.2012.07.011 [doi]
AB  - AIM: Increased basal cortisol secretion has been associated with heightened 
      clinical risk for psychosis, and among at-risk individuals, has been variably 
      related to positive and mood symptoms, as well as clinical outcome. METHODS: 
      Basal salivary cortisol secretion was assessed in 33 patients at clinical high 
      risk (CHR) for psychosis (21 medication-free and 12 taking a serotonin reuptake 
      inhibitor and/or atypical antipsychotic), and 13 healthy controls. Among the CHR 
      patients, we also examined associations of basal salivary cortisol with symptoms 
      (positive, negative, mood, stress sensitivity) and clinical outcome. RESULTS: 
      Basal salivary cortisol secretion was significantly higher in CHR patients who 
      were medication-free compared to CHR patients taking medications and to healthy 
      controls. In this small cohort, basal salivary cortisol secretion was associated 
      at trend level with stress sensitivity, and was not significantly related to 
      other symptoms. CONCLUSIONS: Our finding of elevated basal cortisol secretion in 
      CHR patients supports the premise that excess activation of the HPA axis and/or 
      neuroendocrine abnormalities characterize the psychosis risk state for at least a 
      subset of patients. Our findings further suggest that psychotropic medications 
      may have a normalizing effect on HPA-axis dysfunction in CHR patients, which 
      could potentially inform intervention strategies for the prodrome.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Sugranyes, G
AU  - Sugranyes G
AD  - Servei de Psiquiatria i Psicologia Infantil i Juvenil, Institut de Neurociencies, 
      Hospital Clinic de Barcelona, c. Villarroel 140, 08015 Barcelona, Spain. 
      39987gse@comb.cat
FAU - Thompson, J L
AU  - Thompson JL
FAU - Corcoran, C M
AU  - Corcoran CM
LA  - eng
GR  - K23 MH066279/MH/NIMH NIH HHS/United States
GR  - K23MH066279/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120811
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antipsychotic Agents/therapeutic use
MH  - Child
MH  - Clinical Trials, Phase I as Topic/methods
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Hydrocortisone/*metabolism
MH  - Hypothalamo-Hypophyseal System/*metabolism
MH  - Male
MH  - Pituitary-Adrenal System/*metabolism
MH  - Psychotic Disorders/*drug therapy/metabolism/*physiopathology
MH  - Risk
MH  - Selective Serotonin Reuptake Inhibitors/therapeutic use
MH  - Stress, Psychological/metabolism
MH  - Young Adult
PMC - PMC3463772
MID - NIHMS398568
EDAT- 2012/08/16 06:00
MHDA- 2013/04/06 06:00
PMCR- 2013/11/01
CRDT- 2012/08/16 06:00
PHST- 2012/01/22 00:00 [received]
PHST- 2012/06/23 00:00 [revised]
PHST- 2012/07/16 00:00 [accepted]
PHST- 2012/08/16 06:00 [entrez]
PHST- 2012/08/16 06:00 [pubmed]
PHST- 2013/04/06 06:00 [medline]
PHST- 2013/11/01 00:00 [pmc-release]
AID - S0022-3956(12)00227-0 [pii]
AID - 10.1016/j.jpsychires.2012.07.011 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2012 Nov;46(11):1389-93. doi: 10.1016/j.jpsychires.2012.07.011. 
      Epub 2012 Aug 11.